Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Rating of “Buy” from Brokerages

Janux Therapeutics, Inc. (NASDAQ:JANXGet Free Report) has been given an average recommendation of “Buy” by the twelve brokerages that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a hold recommendation, ten have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $67.70.

JANX has been the topic of several research reports. Leerink Partnrs upgraded shares of Janux Therapeutics to a “strong-buy” rating in a research report on Friday, November 22nd. Wedbush reissued an “outperform” rating and set a $74.00 price target on shares of Janux Therapeutics in a research report on Thursday, August 8th. William Blair restated an “outperform” rating on shares of Janux Therapeutics in a research report on Thursday, November 14th. Cantor Fitzgerald reiterated an “overweight” rating and set a $100.00 price objective on shares of Janux Therapeutics in a research report on Thursday, November 7th. Finally, UBS Group assumed coverage on shares of Janux Therapeutics in a research note on Thursday, October 24th. They issued a “buy” rating and a $69.00 target price for the company.

Check Out Our Latest Report on Janux Therapeutics

Insider Buying and Selling at Janux Therapeutics

In other news, Director Ra Capital Management, L.P. acquired 1,200,000 shares of the company’s stock in a transaction dated Friday, October 18th. The shares were bought at an average price of $44.75 per share, for a total transaction of $53,700,000.00. Following the completion of the purchase, the director now directly owns 9,317,246 shares of the company’s stock, valued at approximately $416,946,758.50. This trade represents a 14.78 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Ventures Xi L.P. Avalon sold 108,365 shares of the company’s stock in a transaction on Friday, September 6th. The shares were sold at an average price of $42.00, for a total transaction of $4,551,330.00. Following the completion of the transaction, the insider now owns 3,162,851 shares of the company’s stock, valued at $132,839,742. This trade represents a 3.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 445,610 shares of company stock worth $20,578,666 in the last quarter. 29.40% of the stock is owned by insiders.

Hedge Funds Weigh In On Janux Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. Franklin Resources Inc. raised its stake in Janux Therapeutics by 64.5% during the third quarter. Franklin Resources Inc. now owns 18,983 shares of the company’s stock valued at $937,000 after buying an additional 7,442 shares in the last quarter. Virtu Financial LLC increased its holdings in shares of Janux Therapeutics by 48.0% in the 3rd quarter. Virtu Financial LLC now owns 7,463 shares of the company’s stock valued at $339,000 after acquiring an additional 2,419 shares during the last quarter. Neo Ivy Capital Management acquired a new stake in shares of Janux Therapeutics during the 3rd quarter valued at approximately $940,000. Geode Capital Management LLC lifted its stake in Janux Therapeutics by 6.2% during the third quarter. Geode Capital Management LLC now owns 662,594 shares of the company’s stock worth $30,107,000 after purchasing an additional 38,490 shares during the last quarter. Finally, Barclays PLC boosted its holdings in Janux Therapeutics by 496.5% in the third quarter. Barclays PLC now owns 174,061 shares of the company’s stock worth $7,907,000 after purchasing an additional 144,883 shares during the period. Institutional investors and hedge funds own 75.39% of the company’s stock.

Janux Therapeutics Trading Down 2.5 %

Shares of Janux Therapeutics stock opened at $45.21 on Tuesday. The company has a 50-day moving average of $49.81 and a two-hundred day moving average of $45.78. The stock has a market cap of $2.37 billion, a PE ratio of -38.64 and a beta of 3.52. Janux Therapeutics has a 12-month low of $7.79 and a 12-month high of $65.60.

Janux Therapeutics (NASDAQ:JANXGet Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.18). Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The firm had revenue of $0.44 million for the quarter, compared to analyst estimates of $1.50 million. The firm’s revenue was down 82.6% compared to the same quarter last year. On average, sell-side analysts forecast that Janux Therapeutics will post -1.35 EPS for the current fiscal year.

About Janux Therapeutics

(Get Free Report

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.

Featured Articles

Analyst Recommendations for Janux Therapeutics (NASDAQ:JANX)

Receive News & Ratings for Janux Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Janux Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.